Mallinckrodt Plc (MNK)

3.08
0.09 2.80
NYSE : Health Technology
Prev Close 3.00
Open 3.04
Day Low/High 2.93 / 3.16
52 Wk Low/High 1.43 / 28.66
Volume 4.58M
Avg Volume 10.59M
Exchange NYSE
Shares Outstanding 84.09M
Market Cap 245.55M
EPS -42.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mallinckrodt To Present At Piper Jaffray Annual Healthcare Conference

Mallinckrodt To Present At Piper Jaffray Annual Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, Nov. 19, 2019 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, Dec.

July 2020 Options Now Available For Mallinckrodt (MNK)

July 2020 Options Now Available For Mallinckrodt (MNK)

Investors in Mallinckrodt plc saw new options begin trading today, for the July 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Mallinckrodt Announces New Clinical Data Evaluating Acthar® Gel (Repository Corticotropin Injection) In Rheumatoid Arthritis (RA) At The 2019 American College Of Rheumatology/Association Of Rheumatology Professionals (ACR/ARP) Annual Meeting

Mallinckrodt Announces New Clinical Data Evaluating Acthar® Gel (Repository Corticotropin Injection) In Rheumatoid Arthritis (RA) At The 2019 American College Of Rheumatology/Association Of Rheumatology Professionals (ACR/ARP) Annual Meeting

-- New analysis from Phase 4 study in RA showed that statistically significant improvement from baseline in patient-reported outcomes for pain, fatigue, physical functioning and work-related impairment was associated with Acthar Gel treatment -

Mallinckrodt Presents Positive Phase 3 Results From Its CONFIRM Study Of Terlipressin In Patients With Hepatorenal Syndrome Type 1 (HRS-1) At The Liver Meeting® 2019

Mallinckrodt Presents Positive Phase 3 Results From Its CONFIRM Study Of Terlipressin In Patients With Hepatorenal Syndrome Type 1 (HRS-1) At The Liver Meeting® 2019

-- Study showed a statistically significant number of patients on terlipressin achieved the primary endpoint of Verified HRS Reversal vs placebo --

Mallinckrodt To Present At Jefferies London Healthcare Conference

Mallinckrodt To Present At Jefferies London Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, Nov. 8, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present at the Jefferies London Healthcare Conference in London on Wednesday, Nov.

Interesting MNK Call Options For December 27th

Interesting MNK Call Options For December 27th

Investors in Mallinckrodt plc saw new options become available today, for the December 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new December 27th contracts and identified the following call contract of particular interest.

Mallinckrodt Announces Data Publication On The Treatment Effectiveness Of Acthar® Gel (Repository Corticotropin Injection) For Resolution Of Multiple Sclerosis Relapse In A U.S. Health Plan Population

Mallinckrodt Announces Data Publication On The Treatment Effectiveness Of Acthar® Gel (Repository Corticotropin Injection) For Resolution Of Multiple Sclerosis Relapse In A U.S. Health Plan Population

-- Previously presented retrospective analysis showed that adult multiple sclerosis relapse patients taking Acthar Gel had a higher relapse resolution rate than those taking other late-line treatments --

Mallinckrodt Plc Announces Exchange Offers And Consent Solicitations

Mallinckrodt Plc Announces Exchange Offers And Consent Solicitations

STAINES-UPON-THAMES, United Kingdom, Nov. 5, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:  MNK) today announced the commencement of private offers (each, an "Exchange Offer" and, collectively, the "Exchange Offers") by its wholly owned subsidiaries,...

Mallinckrodt Plc Reports Earnings And Pipeline Advancements For The Third Quarter 2019 And Raises Adjusted Diluted Earnings Per Share Guidance Range For 2019

Mallinckrodt Plc Reports Earnings And Pipeline Advancements For The Third Quarter 2019 And Raises Adjusted Diluted Earnings Per Share Guidance Range For 2019

- Net sales of $743.7 million with diluted loss per share from continuing operations of $0.01 and adjusted diluted earnings per share (EPS) of $2.07

Mallinckrodt Completes Sale Of BioVectra Inc. For Up To $250 Million

Mallinckrodt Completes Sale Of BioVectra Inc. For Up To $250 Million

-- Milestone reinforces Company's ongoing strategic efforts to focus on branded, high-growth biopharmaceuticals by monetizing a non-core business --

Mallinckrodt Announces UVADEX® (Methoxsalen) Approved In Australia For Use With The THERAKOS® CELLEX® Photopheresis System For Treatment Of Chronic Graft Versus Host Disease (cGvHD) And Skin Manifestations Of Cutaneous T-Cell Lymphoma (CTCL) In Adults

Mallinckrodt Announces UVADEX® (Methoxsalen) Approved In Australia For Use With The THERAKOS® CELLEX® Photopheresis System For Treatment Of Chronic Graft Versus Host Disease (cGvHD) And Skin Manifestations Of Cutaneous T-Cell Lymphoma (CTCL) In Adults

-Approval marks first combined indication label and first regulatory approval in the world for UVADEX in conjunction with the THERAKOS Extracorporeal Photopheresis (ECP) System for the treatment of chronic GvHD in adults-

Interesting MNK Put And Call Options For December 13th

Interesting MNK Put And Call Options For December 13th

Investors in Mallinckrodt plc saw new options begin trading today, for the December 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new December 13th contracts and identified one put and one call contract of particular interest.

Mallinckrodt Raises Awareness Of Critical Role Respiratory Therapists Play In Patient Care During Respiratory Care Week

Mallinckrodt Raises Awareness Of Critical Role Respiratory Therapists Play In Patient Care During Respiratory Care Week

STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, is proud to celebrate Respiratory Care Week ( October 20-26, 2019), and honor the role of respiratory therapists in...

Mallinckrodt To Present Results From Its Pivotal Phase 3 CONFIRM Study Of Terlipressin In Patients With Hepatorenal Syndrome Type 1 (HRS-1) At The Liver Meeting® 2019

Mallinckrodt To Present Results From Its Pivotal Phase 3 CONFIRM Study Of Terlipressin In Patients With Hepatorenal Syndrome Type 1 (HRS-1) At The Liver Meeting® 2019

-- Late-breaker abstract, "A North American Randomized Controlled Trial (RCT) of Terlipressin plus Albumin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)" --

Interesting MNK Put And Call Options For November 29th

Interesting MNK Put And Call Options For November 29th

Investors in Mallinckrodt plc saw new options begin trading today, for the November 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new November 29th contracts and identified one put and one call contract of particular interest.

Mallinckrodt To Report Earnings Results For Third Quarter 2019

Mallinckrodt To Report Earnings Results For Third Quarter 2019

STAINES-UPON-THAMES, United Kingdom, Oct. 9, 2019 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report third quarter 2019 earnings results for the period ended Sept.

MNK November 22nd Options Begin Trading

MNK November 22nd Options Begin Trading

Investors in Mallinckrodt plc saw new options begin trading today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new November 22nd contracts and identified one put and one call contract of particular interest.

Endo, Opioid Producers Said to Mull Unusual Lawsuit Settlement; Shares Rise

Endo, Opioid Producers Said to Mull Unusual Lawsuit Settlement; Shares Rise

The Wall Street Journal reports the companies are considering participating in the bankruptcy proceedings of Purdue Pharma.

Mallinckrodt Announces Positive Top-Line Findings From Its Observational Registry Assessing Relapse Recovery In Multiple Sclerosis Relapse Patients Treated With Acthar® Gel (Repository Corticotropin Injection)

Mallinckrodt Announces Positive Top-Line Findings From Its Observational Registry Assessing Relapse Recovery In Multiple Sclerosis Relapse Patients Treated With Acthar® Gel (Repository Corticotropin Injection)

-- An analysis of 148 patients enrolled in the registry showed patients treated with Acthar Gel reported significant improvements in their MS relapse symptoms at 2 months --

Mallinckrodt Finalizes Settlement To Resolve "Track 1" Opioid Cases With The Ohio Counties Of Cuyahoga And Summit

Mallinckrodt Finalizes Settlement To Resolve "Track 1" Opioid Cases With The Ohio Counties Of Cuyahoga And Summit

-- All named Mallinckrodt entities dismissed with prejudice from the lawsuit --

MNK November 8th Options Begin Trading

MNK November 8th Options Begin Trading

Investors in Mallinckrodt plc saw new options begin trading today, for the November 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new November 8th contracts and identified the following call contract of particular interest.

First Week Of MNK November 15th Options Trading

First Week Of MNK November 15th Options Trading

Investors in Mallinckrodt plc saw new options become available this week, for the November 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new November 15th contracts and identified one put and one call contract of particular interest.

Mallinckrodt Spikes on Positive Regenerative Tissue Treatment Results

Mallinckrodt Spikes on Positive Regenerative Tissue Treatment Results

The company announces positive top-line results from a phase 3 clinical trial of its investigational StrataGraft regenerative tissue.

Mallinckrodt Announces Positive Top-line Results From Pivotal Phase 3 Clinical Trial Of StrataGraft® Regenerative Tissue In Patients With Deep Partial-thickness Thermal Burns

Mallinckrodt Announces Positive Top-line Results From Pivotal Phase 3 Clinical Trial Of StrataGraft® Regenerative Tissue In Patients With Deep Partial-thickness Thermal Burns

- Study met both co-primary endpoints with high statistical significance, demonstrating autograft sparing and durable wound closure at three months with StrataGraft -

Mallinckrodt To Present At Cantor Global Healthcare Conference

Mallinckrodt To Present At Cantor Global Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, Sept. 20, 2019 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present at the Cantor Global Healthcare Conference at the InterContinental New York Barclay, 111 E.

FINAL DEADLINE ALERT - Mallinckrodt Plc (MNK) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders Of Class Action And Lead Plaintiff Deadline: September 24, 2019

FINAL DEADLINE ALERT - Mallinckrodt Plc (MNK) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders Of Class Action And Lead Plaintiff Deadline: September 24, 2019

NEW YORK, Sept. 19, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Mallinckrodt plc (" Mallinckrodt"  or the Company") (NYSE: MNK) and certain of its...

TheStreet Quant Rating: D (Sell)